title: Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
abstract: Hepatitis B virus (HBV) infection can lead to several severe liver diseases, including hepatitis, cirrhosis and hepatocellular carcinoma, although the underlying mechanisms responsible for the clinical outcome have not been well characterized. In this review, we retrospectively examine the history of immunological responses to HBV infection and summarize the current understanding of innate and adaptive immunity in the context of HBV-associated liver disease. Recent data indicate that the interaction between HBV and the host immune response not only substantially drives disease progression, but also significantly influences antiviral efficacy in HBV-infected individuals. Advances in the field have provided insight into the immunopathology of HBV infection. Based on the characteristics of host immune responses in patients with HBV infection, a 'climbing slope hypothesis' is proposed to suggest that therapeutic strategies aimed at modulating the immune activity of the host may represent a complementary approach to antiviral drug treatment for the management of chronically HBV-infected patients.
authors.affiliation: Research Center for Biological Therapy, Beijing 302 Hospital, Beijing 100039, China. fswang@public.bta.net.cn
authors.forename: Fu-Sheng
authors.initials: FS
authors.lastname: Wang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000208:Acute Disease; D056704:Adaptive Immunity / Q000187:drug effects; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000821:virology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007155:Immunologic Factors / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000276:immunology / Q000821:virology; D008113:Liver Neoplasms / Q000276:immunology / Q000821:virology; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007155:Immunologic Factors